US2022079992A1PendingUtilityA1

Spalax fibroblast-derived anti-cancer agents

Assignee: CARMEL HAIFA UNIV ECONOMIC DEVELOPMENT CORP LTDPriority: Jan 10, 2013Filed: Nov 19, 2021Published: Mar 17, 2022
Est. expiryJan 10, 2033(~6.4 yrs left)· nominal 20-yr term from priority
C12N 5/0656A61K 35/33
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A conditioned cell culture medium of cells derived from Spalax or naked mole rat ( Heterocephalus glaber ) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.

Claims

exact text as granted — not AI-modified
1 . A method for treatment of cancer or inhibiting cancer metastasis in a human subject diagnosed with cancer, said method comprising administering to said subject an effective amount of a pharmaceutical composition comprising a conditioned cell culture medium of healthy cells derived from  Spalax  or naked mole rat ( Heterocephalus glaber ), and a pharmaceutically active carrier, excipient or diluent. 
     
     
         2 . The method according to  claim 1 , wherein said cells are derived from  Spalax ehrenbeigi  ( Nannospalax ). 
     
     
         3 . The method according to  claim 1 , wherein said cells are skin or lung fibroblasts. 
     
     
         4 . The method according to  claim 3 , wherein said fibroblasts are primary cells. 
     
     
         5 . The method according to claim I. wherein said cancer is selected from the group consisting of carcinoma, sarcoma, glioma, leukemia and lymphoma. 
     
     
         6 . The method according to  claim 5 , wherein said carcinoma is selected from the group consisting of breast cancer carcinoma, hepatocellular carcinoma and breast adenocarcinoma. 
     
     
         7 . The method according to  claim 1 , further including the concomitant administration of at least one chemotherapeutic agent. 
     
     
         8 . The method according to  claim 1 , wherein said composition further comprises at least one chemotherapeutic agent. 
     
     
         9 . A method for killing cancer cells, inhibiting proliferation of cancer cells or inhibiting cancer cell migration, comprising administering to a human subject in need thereof an effective amount of a pharmaceutical composition comprising a conditioned cell culture medium of healthy cells derived from  Spalax  or naked mole rat ( Heterocephalus glaber ), and a pharmaceutically active carrier, excipient or diluent. 
     
     
         10 . The method according to  claim 9 , wherein said cells are derived from  Spalax ehrenbergi  ( Nannospalax ). 
     
     
         11 . The method according to  claim 9 , wherein said cells are skin or lung fibroblasts. 
     
     
         12 . The method according to  claim 11 , wherein said fibroblasts are primary cells. 
     
     
         13 . The method according to  claim 9 , wherein said cancer cells are selected from the group consisting of carcinoma cells, sarcoma cells, glioma cells, leukemia cells and lymphoma cells. 
     
     
         14 . The method according to  claim 13 , wherein said carcinoma cells are selected from the group consisting of breast cancer carcinoma cells, hepatocellular carcinoma cells and breast adenocarcinoma cells. 
     
     
         15 . The method according to  claim 9 , further including the concomitant administration of at least one chemotherapeutic agent. 
     
     
         16 . The method according to  claim 9 , wherein said composition further comprises at east one chemotherapeutic agent.

Join the waitlist — get patent alerts

Track US2022079992A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.